<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02627443</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-02064</org_study_id>
    <secondary_id>NCI-2015-02064</secondary_id>
    <secondary_id>MC1563</secondary_id>
    <secondary_id>9948</secondary_id>
    <secondary_id>9948</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>UM1CA186686</secondary_id>
    <nct_id>NCT02627443</nct_id>
  </id_info>
  <brief_title>Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer</brief_title>
  <official_title>Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase I/II trial studies the side effects and how well carboplatin and
      gemcitabine hydrochloride with or without ATR kinase inhibitor VX-970 work in treating
      patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back
      (recurrent) and has spread to other places in the body (metastatic). Drugs used in
      chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to
      stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
      or by stopping them from spreading. ATR kinase inhibitor VX-970 may stop the growth of tumor
      cells by blocking some of the enzymes needed for cell growth. Giving carboplatin and
      gemcitabine with or without ATR kinase inhibitor VX-970 may work better in treating ovarian,
      primary peritoneal, or fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Assess safety and tolerability of the combination therapy carboplatin, gemcitabine
      (gemcitabine hydrochloride) and VX-970 (rad3-related [ATR] kinase inhibitor VX-970) in adult
      women with platinum sensitive recurrent high grade serous or high grade endometrioid ovarian,
      primary peritoneal or fallopian tube cancer. (Phase I Dose Escalation/Safety Lead-in) II.
      Determine the dose of the triple therapy to be used in the randomized phase 2 portion of the
      study. (Phase I Dose Escalation/Safety Lead-in) III. To determine whether the addition of
      VX-970 to standard carboplatin/gemcitabine increases the progression free survival (PFS) when
      compared to carboplatin/gemcitabine alone in patients with first recurrence of platinum
      sensitive high grade serous or endometrioid ovarian, primary peritoneal or fallopian tube
      carcinoma. (Randomized Phase 2)

      SECONDARY OBJECTIVES:

      I. To determine whether the addition of VX-970 to carboplatin and gemcitabine increases
      overall survival (OS) compared to carboplatin and gemcitabine alone in first recurrence
      platinum sensitive disease.

      II. To determine whether the addition of VX-970 to carboplatin and gemcitabine increases the
      confirmed response rate (RR) compared to carboplatin and gemcitabine alone in first
      recurrence platinum sensitive disease.

      III. To describe and compare adverse events between the two arms.

      TERTIARY OBJECTIVES:

      I. To determine whether increased deoxyribonucleic acid (DNA) damage as assessed by multiplex
      assay correlates with response to combination therapy with VX-970.

      II. To determine whether mutations in homologous recombination repair genes correlate with
      response to combination therapy with VX-970.

      III. Assess a limited pharmacokinetic profile of VX-970 and gemcitabine when given in
      combination with carboplatin.

      IV. To ascertain modulation of ATR autophosphorylation and other pharmacodynamic readouts for
      ATR inhibition by VX-970.

      OUTLINE: This is a phase I, dose-escalation study of gemcitabine hydrochloride and ATR kinase
      inhibitor VX-970 followed by a phase II study. Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive carboplatin intravenously (IV) over 30 minutes on day 1, gemcitabine
      hydrochloride IV over 30 minutes on days 1 and 8, and ATR kinase inhibitor VX-970 IV over 60
      minutes on days 2 and 9.

      ARM II: Patients receive carboplatin IV over 30 minutes on day 1 and gemcitabine
      hydrochloride IV over 30 minutes on days 1 and 8.

      In both arms, courses repeat every 21 days in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2016</start_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria</measure>
    <time_frame>Time from randomization to the first of either disease progression or death from any cause, assessed up to 3 years</time_frame>
    <description>The one-sided log-rank test will be used to compare PFS between the 2 treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Time from study entry to death from any cause, assessed up to 3 years</time_frame>
    <description>OS will be estimated using the Kaplan-Meier method, and the log-rank test will be used to compare the 2 treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed response rate per RECIST 1.1 criteria</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with a confirmed response will be calculated and compared between the 2 arms using a Chi-square or Fisher's exact test. The 95% confidence intervals will also be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the Chi-square or Fisher's exact test.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in the frequency of marker inhibition</measure>
    <time_frame>Baseline to up to 3 years</time_frame>
    <description>Semi-quantitative data will be used to compare the data between the treatment arms using boxplots and descriptive statistics.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>High Grade Ovarian Serous Adenocarcinoma</condition>
  <condition>Ovarian Endometrioid Tumor</condition>
  <condition>Recurrent Fallopian Tube Carcinoma</condition>
  <condition>Recurrent Ovarian Carcinoma</condition>
  <condition>Recurrent Primary Peritoneal Carcinoma</condition>
  <condition>Stage IV Fallopian Tube Cancer AJCC v6 and v7</condition>
  <condition>Stage IV Ovarian Cancer AJCC v6 and v7</condition>
  <condition>Stage IV Primary Peritoneal Cancer AJCC v7</condition>
  <arm_group>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carboplatin IV over 30 minutes on day 1, gemcitabine hydrochloride IV over 30 minutes on days 1 and 8, and ATR kinase inhibitor VX-970 IV over 60 minutes on days 2 and 9. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (carboplatin, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive carboplatin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATR Kinase Inhibitor VX-970</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <other_name>VX-970</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, gemcitabine hydrochloride)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, gemcitabine hydrochloride)</arm_group_label>
    <other_name>dFdCyd</other_name>
    <other_name>Difluorodeoxycytidine Hydrochloride</other_name>
    <other_name>Gemzar</other_name>
    <other_name>LY-188011</other_name>
    <other_name>LY188011</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (carboplatin, gemcitabine hydrochloride, VX-970)</arm_group_label>
    <arm_group_label>Arm II (carboplatin, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed high grade serous or endometrioid ovarian, peritoneal or
             fallopian tube malignancy that is metastatic and for which curative measures do not
             exist; pathology must be reviewed and confirmed at Mayo Clinic Department of
             Pathology; the histology can be confirmed from tissue that was taken at the time of
             diagnosis; a biopsy at the time of recurrence prior to enrollment on study is not
             required

          -  Patients must have measurable disease, defined as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded for
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm (&gt;= 2 cm) with
             conventional techniques or as &gt;= 10 mm (&gt;= 1 cm) with spiral computed tomography (CT)
             scan, magnetic resonance imaging (MRI), or calipers by clinical exam

          -  Patients must be in their first platinum sensitive recurrence; this is defined as
             recurrence that occurred greater than six months after completion of first line
             platinum based therapy; for the phase 1 portion of the study, patients must have a
             platinum free interval between 6 months and 1 year and are not eligible or unwilling
             to undergo a second cytoreductive surgery

          -  Children are excluded from this study, but will be eligible for future pediatric
             trials

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  Life expectancy of greater than 6 months

          -  Leukocytes &gt;= 3,000/mcL

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2 Ã— institutional upper limit of normal (ULN)

          -  Creatinine within normal institutional limits OR creatinine clearance &gt;= 50
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Negative serum pregnancy test result for females of child bearing potential

          -  Women of child-bearing potential must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry, for the duration of
             study participation, and 6 months after completion of VX-970 administration; should a
             woman become pregnant or suspect she is pregnant while she is participating in this
             study, she should inform her treating physician immediately

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
             the study or those who have not recovered from adverse events due to agents
             administered more than 4 weeks earlier, excluding alopecia; patients with treatment
             related effects, such as peripheral neuropathy, that are grade 1 or less are eligible

          -  Prior exposure to gemcitabine

          -  Patients who are receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to VX-970, carboplatin, gemcitabine or to these specific compounds

          -  VX-970 is primarily metabolized by cytochrome P450, family 3, subfamily A, polypeptide
             4 (CYP3A4); therefore, concomitant administration with strong inhibitors or inducers
             of CYP3A4 should be avoided

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Pregnant women are excluded from this study, breastfeeding should be discontinued if
             the mother is treated with VX-970; these potential risks also apply to the other
             agents used in this study, such as carboplatin and gemcitabine

          -  Patients with Li Fraumeni syndrome are excluded from the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Wahner Hendrickson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Andrea E. Wahner Hendrickson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

